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Primary PCIAbstract Background: Glycoprotein IIb/IIIa inhibitor therapy during primary percutaneous
coronary intervention (PCI) decreases the incidence of major adverse cardiac events.
Aim: To study the impact of high bolus dose tiroﬁban on left ventricular ejection fraction in
patients with acute anterior ST segment elevation MI treated with primary PCI.
Patients and methods: Forty patients presenting to Ain Shams University, and specialized hospitals
with the diagnosis of acute anterior STEMI were treated with primary PCI. Twenty patients were
given conventional intravenous bolus dose tiroﬁban (10 lg/kg) upstream prior to primary angio-
plasty and twenty patients were given intravenous high bolus dose tiroﬁban (25 lg/kg) upstream
prior to PCI. In-hospital follow up was done including echocardiography, and serial cardiac
enzymes in addition to clinical follow up for MACE and bleeding complications.
Results: Successful primary angioplasty was attained in all patients. The LV systolic function
was signiﬁcantly better in the high bolus dose group in comparison to the conventional bolus
dose groups (48% vs 41%, P< 0.01). The incidence of recurrent ischemia was statistically non-
signiﬁcant between the two groups (5% vs 25%, P> 0.05). Both regimens were safe and the
bleeding complications were minimal and did not differ between the study groups.
Conclusion: In patients presenting with acute anterior STEMI and treated with primary PCI, the
high bolus dose tiroﬁban given intravenously upstream prior to PCI seems to be a safe and effective
regimen to achieve a better left ventricular ejection fraction in comparison to the conventional bolus
dose regimen, without increasing the risk of bleeding.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Acute myocardial infarction (AMI) remains a public health
problem of epidemic proportions. Recent data from the
American Heart Association (AHA) reveal a prevalence of
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age, sex, and ethnicity.1 Primary percutaneous coronary inter-
vention (PCI) in patients with AMI has been shown to be pref-
erable to thrombolytic therapy in terms of patient survival,
higher rates of patency in the infarcted arteries, and lower rates
of reinfarction and stroke.2,3 These beneﬁts of PCI can be fur-
ther enhanced by administration of platelet glycoprotein IIb/
IIIa inhibitors abciximab,4,5 or eptiﬁbatide.6,7 Tiroﬁban8
stands out as a potentially useful adjunct to PCI because it is
a small non-peptide molecule, somewhat similar to eptiﬁba-
tide, and does not elicit an adverse immune reaction. Com-
pared with abciximab, its advantages as an adjunct therapy
for PCI are lower cost and no overt bleeding complications.9
Results from studies of the efﬁcacy of adjunctive tiroﬁban in
patients undergoing PCI have been inconsistent.10–12 Some
have shown beneﬁcial angiographic and clinical outcomes,13,11
whereas others show either no beneﬁt14 or modest initial clin-
ical improvements, unsustained at 30-day follow-up.15 Inter-
pretation of these results is difﬁcult because different dosing
regimens were used; for example, tiroﬁban was administered
at a conventional dose (10 lg/kg bolus followed by 0.15 lg/
kg/min for 18–36 h) in some studies10,12 and in others16,17 at
a high dose (20–25 lg/kg bolus followed 0.15 lg/kg/min for
18–24 h). The conventional dose of tiroﬁban may not achieve
adequate platelet aggregation inhibition compared with abcix-
imab.18,19 So, this study was done to clarify the effect of high
bolus dose tiroﬁban on left ventricular ejection fraction in
patients with acute anterior myocardial infarction treated with
primary coronary intervention in comparison to the standard
bolus dose.
1.1. Aim of study
To study the impact of high bolus dose tiroﬁban given
upstream in ER on left ventricular ejection fraction (early in-
hospital) in patients with acute anterior ST segment elevation
MI treated with primary percutaneous coronary intervention.
2. Methods
2.1. Study population
This randomized study was conducted on 40 patients who
came to the emergency room complaining of acute chest pain
and diagnosed as having acute anterior ST segment elevation
myocardial infarction during the year 2010. The method of
randomization was the ﬁrst suitable one (fulﬁlling the inclusion
criteria) was chosen for group I and the second one for group
II, the third suitable one for group I, and so on. All patients
were treated by primary percutaneous coronary intervention.
The following patients were included in this study: males and
females with age between 20 and 70 years presenting with
acute chest pain and ST elevation indicative of myocardial
infarction, as proposed by the Joint Committee of the
European Society of Cardiology (ESC) and American College
of Cardiology (ACC), a new ST segment elevation in 2 or
more contiguous leads of at least 1 mm at the J point in the
anterior leads (V1–V6, I, aVL)20 with a feasibility to perform
PCI within 6 h from onset of symptoms. Patients who have
one or more of the following were excluded from the study:
Contraindications for antiplatelets such as bleeding disorderincluding gastrointestinal bleeding, hematuria, or known pres-
ence of occult blood in the stool prior to randomization,
thrombocytopenia (Platelet count < 100.000/cm3), systolic
blood pressure persistently exceeding 200 mmHg and/or dia-
stolic blood pressure exceeding 110 mmHg at time of enroll-
ment, recent (<6 months) stroke, patients with severe renal
failure (on hemodialysis), patients with recent (<30 days)
major surgery, previous CABG, patients with previous MI,
patients who presented more than 6 h from onset of symptoms,
patients with known cardiomyopathy and patients who
refused to be enrolled in the study.
The patients were divided randomly into two groups
according to the bolus dose of tiroﬁban:
Group (I): It included 20 patients who received the conven-
tional single intravenous bolus dose of tiroﬁban upstream
in the emergency room prior to primary PCI (10 lg/kg over
3 min).
Group (II): It included 20 patients who received a high
intravenous bolus dose of tiroﬁban upstream in the emer-
gency room prior to primary PCI (25 lg/kg).2.2. Procedures
All patients were subjected to thorough history taking for the
presence of cardiovascular risk factors such as smoking,
hypertension, diabetes mellitus, dyslipidemia and family his-
tory of ischemic heart disease. The patients underwent clinical
assessment on admission to the ER. They were classiﬁed into 4
classes according to Killip classiﬁcation. Class 1: patients with
no abnormal clinical ﬁndings, class 2: patients with pulmonary
congestion, elevated jugular venous pressure or having S3 gal-
lop, class 3: patients with pulmonary edema and class 4:
patients with cardiogenic shock. Emergency 12 lead surface
ECG was done and analyzed for ST segment elevation of
>1 mV in 2 adjacent ECG anterior leads, ST segment depres-
sion in the reciprocal leads, evidence of old MI (pathological
Q waves), and conduction defects. Cardiac biomarkers were
performed by using total CK and CK-MB fraction on admis-
sion and then serially every 8 h for 24 h, then daily till normal-
ization, together with full laboratory. The bolus dose of
tiroﬁban was given randomly to the patients according to
the group and all patients continued on tiroﬁban (0.15 lg/
kg/min continuous infusion) for 48 h post procedure, in addi-
tion to half dose unfractionated heparin or low molecular
weight heparin. By using the modiﬁed Seldinger technique,
coronary angiography was done by using femoral artery punc-
ture, and Target Vessel Revascularization (LAD) was per-
formed by using balloon dilatation ± stenting. Informed
consent was obtained before the intervention. Qualiﬁed
patients received aspirin (300 mg) and clopidogrel (600 mg)
before the PTCA procedure. Operators were provided with
guidelines for heparin administration during PTCA that rec-
ommended a maximum heparin bolus of 10000 U before the
procedure. In the stented patients, clopidogrel 75 mg daily
for at least 4 weeks was administered. All patients continued
to receive aspirin 150 per day. Other medications, including
b-blockers, ACE inhibitors, nitrates, statins and morphine
were administered according to the patient’s condition.
Patients were discharged after normalization of cardiac
enzymes and achieving clinical stabilization.
Table 1 Baseline clinical characteristics of the study groups.
Group I Group II P value
Mean age (years) 53.75 55.05 >0.05
Males No (%) 17 (85%) 17 (85%) >0.05
Females No (%) 3 (15%) 3 (15%) >0.05
Smoking No (%) 16 (80%) 12 (60%) >0.05
Family history No (%) 2 (10%) 4 (20%) >0.05
Hypertension No (%) 9 (45%) 10 (50%) >0.05
DM No (%) 9 (45%) 7 (35%) >0.05
Dyslipidemia No (%) 4 (20%) 6 (30%) >0.05
Killip class No (%)
1 19 (95%) 20 (100%) >0.05
2 0 0 >0.05
3 0 0 >0.05
4 1 (5%) 0 >0.05
Door to balloon time (min) 84.20 86.65 >0.05
Total ischemic time (min) 264.2 278.65 >0.05
Mean Total CK 3012.75 2494.55 >0.05
Mean CK-MB 321.05 278.35 >0.05
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Primary end point: left ventricular ejection fraction assessed by
transthoracic echocardiography using the Simpson method
was done for all patients after normalization of their cardiac
enzymes (in the third or fourth day post PCI) using a
2.5 MHz mechanical transducer mounted on a GE Vivid 5
machine with the patient in the left lateral position from the
apical 4 chamber view.
Secondary end points: Major adverse cardiovascular event
(MACE) (such as death, recurrent ischemia, etc.), target vessel
revascularization (TVR) and bleeding complications including
major bleeding, minor bleeding and puncture site bleeding
were included as secondary end points.
2.4. Data management
Data were collected, veriﬁed, revised and then edited on the
P.C. The data were then analyzed statistically by using SPSS
statistical package version (16). The following tests were done:
X=Mean, SD = Standard deviation, T test for independent
samples, ANOVA= Analysis of variance, X2 = Chi square
test, Post Hoc test. P value > 0.05 = Non-signiﬁcant (NS),
P value < 0.05 = Signiﬁcant (S) and P value < 0.01 =
Highly signiﬁcant (HS).Table 2 The intervention characteristics between the two
groups.
Group I Group II P value
Proximal LAD 18 (90%) 19 (95%) >0.05
PTCA No (%) 20 (100%) 19 (95%) >0.05
Stenting No (%) 20 (100%) 19 (95%) >0.05
Stent size (mm) 3.11 · 23.05 3.11 · 22.30 >0.053. Results
The study was conducted on 40 patients who came to the
emergency room at Ain Shams University and Ain Shams Uni-
versity Specialized Hospitals during the year 2010 complaining
of acute chest pain and diagnosed as having acute anterior ST
segment elevation myocardial infarction. All patients were
treated by primary percutaneous coronary intervention. The
angioplasty procedure was done successfully for all patients
targeting only the culprit lesion in the infarct related artery
(left anterior descending artery).
3.1. Baseline clinical characteristics
Table 1 identiﬁes the baseline characteristics of the patients in
the study. The mean age was about 54 years and more than
80% were males in all study groups. Baseline characteristics
were similar in between the two study groups with no statisti-
cal signiﬁcance (P> 0.05). It was found that 80% of group I
were smokers whereas 60% of group II were smokers. 10% of
group I have a family history of coronary artery disease and
20% of group II have a family history of IHD. 45% of group
I were hypertensives, 50% of group II were hypertensives. 45%
of group I were diabetics, 35% of group II were diabetics.
Dyslipidemia was present in 20% in group I and 30% in group
II. At presentation, Killip class 1 was present in 95% of group
I, 100% of group II. No patients in Groups I and II were clas-
siﬁed as Killip class 2. Killip class 3 was absent in all groups.
5% of group I were classiﬁed as Killip class 4 and no patients
in group II were classiﬁed as Killip class 4. The mean door to
balloon time in group I was 84.20 min and in group II was
86.65 min. The mean total ischemic time (from onset of chest
pain to balloon) was 264.2 min in group I and 278.65 min in
group II. Early peaking of the total CK was observed, postintervention, in nearly all patients in the sample taken after
reperfusion signifying successful reperfusion. In group I, the
mean peak CK was 3012.75 and the mean peak CK-MB was
321.05 while in group II, the mean peak CK was 2494.55
and the mean peak CK-MB was 278.35.
3.2. Intervention characteristics
Table 2 identiﬁes the intervention characteristics. PTCA and
stenting (for LAD) was done for all patients in group I and
all patients in group II except one patient who had recanalized
LAD. 18 patients in group I were having proximal LAD occlu-
sion while 2 patients had mid LAD occlusion. While in group
II, all patients except the one with recanalized LAD, had prox-
imal LAD occlusion (P> 0.05). All stents were bare metal
stents. In group I the mean stent size was 3.11 · 23.05 mm
and in group II, the mean stent size was 3.11 · 22.30 mm.
All parameters were statistically non-signiﬁcant between the
two groups (P> 0.05).
3.3. End points
Table 3 identiﬁes the end points of the study. During hospital
stay, all patients were assessed by trans-thoracic echocardiog-
raphy on the 3rd or 4th day post PCI (after normalization of
cardiac enzymes). The LV systolic function (EF) was better
in the high bolus dose group (mean EF was 49%) with a highly
signiﬁcant difference in comparison to the standard bolus dose
(42% in group I) (P< 0.01) (see Figs. 1 and 2).
Table 3 LV EF and MACCE between the two groups.
Group I Group II P value
Mean EF (%) 41.65 48.95 <0.01
Recurrent ischemia No (%) 5 (25%) 1 (5%) >0.05
Death No (%) 1 (5%) 0 >0.05
TVR No (%) 0 0 >0.05
Major bleeding No (%) 0 0 >0.05



















Figure 2 Distribution of recurrent ischemia among the study
groups.
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patient stabilization). The incidence of recurrent ischemia dur-
ing hospital stay was 25% (5 patients) in group I and 5% (1
patient) in group II (P> 0.05). Only one patient in group I
died during his hospital stay, whereas all patients in group II
were discharged alive from the hospital (P> 0.05). None of
the patients needed urgent target vessel revascularization dur-
ing hospital stay. In the present study, the high bolus dose of
tiroﬁban was safe and the bleeding complications were mini-
mal and did not differ between the study groups (P> 0.05).
4. Discussion
The administration of glycoprotein IIb/IIIa inhibitors is con-
sidered to provide additional beneﬁt to mechanical reperfusion
in the treatment of patients with ST elevation myocardial
infarction and is included as a class-IIa recommendation in
the Guidelines for Percutaneous Coronary Intervention of
the European Society of Cardiology.21 The efﬁcacy of tiroﬁban
in ST-segment elevation myocardial infarction (STEMI) hasbeen demonstrated when administered in patients being man-
aged with primary percutaneous coronary intervention
(PCI).22 The beneﬁts of the use of tiroﬁban in patients with
ST elevation myocardial infarction treated with PCI have
raised the question whether early treatment with this inhibitor,
with the aim to improve initial patency before intervention,
may further improve outcome.23 The conventional dose of tir-
oﬁban may not achieve adequate platelet aggregation inhibi-
tion compared with abciximab.18,19,24 This is likely to
inﬂuence the results, so, this study was done to clarify the
effect of high bolus dose tiroﬁban on left ventricular ejection
fraction in patients with acute anterior ST segment elevation
MI treated with primary percutaneous coronary intervention.
The clinical and demographic data (age, sex, risk factors,
Killip class) were statistically non-signiﬁcant in-between
groups. Also, the time to treatment which is the door to needle
time and door to balloon time were both statistically non-sig-
niﬁcant in-between the study groups. These baseline character-
istics were also statistically non-signiﬁcant in the studies done
by Tuba et al. (2006)25 who compared the high bolus dose reg-
imen with the standard regimen. Also, these factors were statis-
tically non-signiﬁcant in the study done by Emre et al. (2006)26
who evaluated the effect of early tiroﬁban on myocardial sal-
vage and cardiovascular outcome in patients with acute myo-
cardial infarction (AMI) undergoing infarct-related artery
stenting. As the success rate is inversely correlated to the dura-
tion of symptoms, also is inversely correlated to the time to
treatment,27 so, in this study the door to needle time and door
to balloon time were tried to be nearly in the same range in all
groups (door to needle time was around 30 min and door to
balloon time was around 90 min in all study groups) in order
not to affect the angiographic results. The door to balloon time
was statistically non-signiﬁcant in-between groups. This is
matching with the AHA/ACC guidelines for ST-segment ele-
vation MI which recommend door-to-balloon time less than
90 min.27 When the cardiac biomarkers (peak cardiac enzymes
post procedure) of the patients were demonstrated, early peak-
ing of the total CK was observed in nearly all of the patients in
the sample taken after reperfusion signifying successful reper-
fusion. The mean total CK and CK-MB were lower in the dou-
ble bolus group, but when compared to the other group, it was
statistically non-signiﬁcant. The cardiac biomarkers, creatine
kinase (CK), CK-MB, and troponins T and I are routinely
measured after myocardial infarction. However, their correla-
tion with functional and clinical outcomes after PCI for
STEMI is not well established as said by Chia et al. (2008)28
who studied the utility of Cardiac Biomarkers in Predicting
Infarct Size, Left Ventricular Function, and Clinical Outcome
After Primary Percutaneous Coronary Intervention for ST-
Segment Elevation Myocardial Infarction and found that
assessment of TnI72h after primary PCI is the most sensitive
and speciﬁc method to estimate infarct size, LVEF, and poten-
tially useful for risk stratiﬁcation. Most of the patients in pres-
ent study had coronary bare- metal stent implantation and so,
as most of the patients in all studies e.g. Advance trial,13 the
study done by Tuba et al. in 2006,25 the study done by Bilsel
et al. in 2006,29 the study done by Shyh-Ming et al. in
2006,30 the one done by Gunasekara et al. in 20069 and the
one done by van’t Hof and Valgimigli in 2009.22 During hos-
pital stay, all patients were assessed by trans-thoracic echocar-
diography. The LV systolic function was better in the high
bolus dose group with a highly signiﬁcant difference in
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et al. (2006),25 the LVEF at 1 month was similar between the
high bolus does group and the standard bolus dose, while
the in-hospital EF was not mentioned. In the Tuba study, there
was no continuous tiroﬁban infusion after the high bolus dose,
and this may signify the importance of tiroﬁban infusion after
the bolus dose. Also, Danzi et al. (2004)31 in their study con-
cluded that high bolus dose tiroﬁban and abciximab were sim-
ilar in recovery in LV systolic function after one month, and
this indicates the efﬁcacy of high bolus dose tiroﬁban as abcix-
imab. In the study done by Taglieri et al. (2009),32 there was no
difference in LV function recovery in patients undergoing pri-
mary PCI treated either with abciximab or high-dose bolus tir-
oﬁban. In the present work, the MACEs were recorded in all
patients during their hospital stay, and the result was that
the recurrent ischemia was statistically not signiﬁcant between
the study groups. Death and target vessel revascularization
were statistically non-signiﬁcant in-between groups. In the
RESTORE trial, which compared the conventional tiroﬁban
dose with a placebo in patients presenting with acute MI or
acute coronary syndrome and undergoing PCI, tiroﬁban pro-
tects against early adverse cardiac events related to thrombotic
closure. At 30 days, however, the reduction in adverse cardiac
events was no longer statistically signiﬁcant.33 This unsu-
stained clinical beneﬁt indicates that the conventional dose
of tiroﬁban may not achieve adequate platelet aggregation
inhibition and so, it remains unclear what the optimal regimen
of adjunctive tiroﬁban therapy would be for PCI.11 In the
ADVANCE trial, the high bolus dose tiroﬁban reduced the
MACE (death, recurrent ischemia, and TVR) in comparison
to placebo.13 In contrast to the present study, a study done
by Tuba et al. (2006)25 revealed that the high bolus dose regi-
men was associated with a higher incidence of reinfarction
than the standard regimen during follow up (1 month). But
this difference could be explained, as in Tuba study the high
bolus dose was a single dosing regimen with no continuous tir-
oﬁban infusion after. Also, in the study done by Shyh-Ming
et al. (2006),30 the high bolus dose tiroﬁban regimen was supe-
rior to the conventional dosing regimen in reducing the MACE
at one month and one year, but this was statistically non-sig-
niﬁcant. In the study done by Gunasekara et al. (2006),9 the
high bolus dose tiroﬁban was as effective as abciximab in
reducing the MACE. The results of Gunasekara study were
conﬁrmed in the MULTISTRATEGY trial34 and in the FATA
study.35 Also, tiroﬁban was as effective as eptiﬁbatide in reduc-
ing MACE and 30 days mortality in a study done by Yasser
Sadek et al.36 The On-TIME (Ongoing Tiroﬁban in Myocar-
dial Infarction Evaluation) 2 trial22 assessed early administra-
tion of the high-dose bolus regimen of tiroﬁban either at
referral center or in the ambulance, in patients being trans-
ferred to a primary PCI center in comparison to a placebo.
Early use of high bolus dose tiroﬁban resulted in both a signif-
icant increase in the rate of complete resolution of ST-segment
deviation pre- and post-PCI, and improvement in clinical out-
comes at 30 days. This study showed high bolus dose tiroﬁban
to be a well-tolerated and effective GP IIb/IIIa inhibitor in the
management of patients with STEMI. In the present work, the
two groups of tiroﬁban did not differ statistically regarding the
bleeding complications (major bleeding, minor bleeding and
puncture site bleeding). These results were similar to most of
the studies done comparing high bolus dose tiroﬁban with aplacebo,23,13 comparing the high bolus dose tiroﬁban with
the standard bolus dose,26,31 comparing the high bolus dose
with abciximab or eptiﬁbatide.9,34–365. Summary
This study was done to clarify the effect of high bolus dose
tiroﬁban on left ventricular ejection fraction in patients with
acute anterior ST segment elevation MI treated with primary
percutaneous coronary intervention. The study was con-
ducted on 40 patients who came to the emergency room at
Ain Shams University and Ain Shams University specialized
hospitals complaining of acute chest pain and were diagnosed
as having acute anterior ST segment elevation myocardial
infarction. All patients were treated by primary percutaneous
coronary intervention. The high bolus dose tiroﬁban given
intravenously upstream prior to PCI seems to be a safe and
effective regimen to achieve a better left ventricular ejection
fraction in comparison to the conventional bolus dose regi-
men, without increasing the risk of bleeding. This effect could
be explained by the achievement of high drug concentration
in the blood and subsequently higher degree of inhibition
of platelet aggregation.
6. Conclusion
In patients presented with acute anterior STEMI and treated
with primary PCI, the high bolus dose tiroﬁban given intrave-
nously upstream prior to PCI seems to be a safe and effective
regimen to achieve a better left ventricular ejection fraction in
comparison to the conventional bolus dose regimen, without
increasing the risk of bleeding.
7. Recommendations
A larger sample size with longer term follow up regarding left
ventricular systolic function (e.g. after 1 month and after
6 months) is required to add beneﬁt to the current study. Com-
parison between high bolus dose tiroﬁban and intracoronary
bolus dose tiroﬁban in patients with acute anterior STEMI
treated with primary coronary intervention regarding
myocardial salvage and left ventricular systolic function is also
recommended.
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